Transfemoral transcatheter aortic valve replacement for pure aortic regurgitation

Surgical aortic valve replacement continues to be the preferred method for treating severe aortic regurgitation.1 For patients who encounter prohibitively high surgical risks, transcatheter aortic valve implantation (TAVI) is increasingly becoming a viable substitute. Originally developed for treating aortic-valve stenosis in patients with high surgical risk, TAVI's role has expanded to address pure, degenerative aortic regurgitation—a pathology frequently identified in older patients (>70 years) with multiple comorbidities.